Strategic Intake

INITIATE R&D DUE DILIGENCE

Name: IOC Ltd. (Olympia Biosciences™)
Address: ul. Polska 20, Gdynia, Pomeranian, 81-339, PL
Telephone: +48 58 710 24 64
Price range: $$$$

This terminal is for enterprise mandates only: IP-critical programs, regulatory ownership, and funded execution pathways. Commodity briefs, lowest-MOQ scouting, and open advisory requests are declined at intake.

INITIATE R&D DUE DILIGENCE REQUEST Q4 ALLOCATION

0

CONSUMER BRANDS OWNED

STRUCTURAL CONFLICT ELIMINATION
17

YEARS WITHOUT QA CLAIMS

AUDITED RECORD SINCE 2009
80%

PROJECTS DECLINED

ADMISSION FILTER PROTECTS EXECUTION
Cpk > 1.33

SCALE-UP THRESHOLD

PPQ-ALIGNED PROCESS CAPABILITY

Who gets admitted

This intake is designed for operators with something meaningful to defend: differentiated science, regulated ambition, or strategic transfer economics.

A protected IP thesis, medical differentiation, or enterprise transfer mandate.
Decision-makers with authority over budget, formulation, supply chain, or diligence.
A serious commercial horizon: launch, acquisition, clinic platform, or scale-up.
Willingness to begin with a Paid Discovery allocation when admitted.

What the Paid Discovery allocation covers

Paid discovery is not a sales gimmick. It is the filter that protects executive time, scientific depth, and downstream execution quality.

Executive scientific triage of the commercial thesis, dosage form, and regulatory pathway.
A confidential recommendation on formulation path, transfer risk, and scale feasibility.
An admission decision for deeper R&D, validation, and manufacturing work.

Fast-track for qualified operators

INITIATE R&D DUE DILIGENCE

If your team already has an MBR, dossier, clinic concept, or transfer mandate, you can skip directly to an executive qualification call with our scientific leadership.

REQUEST Q4 ALLOCATION

Qualification starts at 5,000 units per SKU. Enterprise programs scale to 100M+ capsules per month. Admission standards stay intentionally high to protect partner outcomes.

TRANSMIT THE WRITTEN QUALIFICATION DOSSIER

Tell us what must be protected, proven, or scaled.

Use the brief to describe the commercial thesis, scientific edge, and operational mandate. We read for seriousness, clarity, and fit.

Full Name*

Work Email*

Company / Fund / Clinic*

Your Mandate*

Programme Budget Envelope*

PAID DISCOVERY REQUIRED · PROGRAMMES BELOW MINIMUM THRESHOLD ARE ROUTED TO ASYNCHRONOUS REVIEW

Primary Mandate*

Strategic Brief*

Qualification starts at 5,000 units per SKU. Enterprise programs scale to 100M+ capsules per month. Admission standards stay intentionally high to protect partner outcomes.

Request mutual NDA before technical disclosure
If the brief contains sensitive formulation IP or diligence material, we can move into mutual NDA before any substantive technical exchange.

I consent to Olympia Biosciences™ (Olympia Biosciences™ Ltd.) processing my personal data submitted in this form for the purpose of responding to my B2B inquiry, in accordance with the Privacy Policy. Consent may be withdrawn at any time by contacting us directly. (GDPR Art. 7 / CCPA)

What happens after submission

1
Your brief is triaged by executive scientific leadership, usually within one business day.
2
If the mandate fits, we move under NDA where required and schedule a qualification call or technical briefing.
3
Qualified projects receive a paid discovery scope, strategic recommendation, or a direct decline to protect everyone’s time.

Official email

Loading email...

Global switchboard

+48 58 710 24 64

Headquarters

Olympia Biosciences™ Ltd. (Olympia Biosciences™)
ul. Polska 20
81-339 Gdynia, Poland (EU)

Certifications

ISO 9001 · ISO 22000 · ISO 22716 · ISO 27001 · GMP/HACCP · U.S. FDA Registered

INITIATE R&D DUE DILIGENCE

Tell us what must be protected, proven, or scaled.

Qualification brief received.